Mirati Therapeutics, Inc.
MRTX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $16,400 | $13,690 | $7,167 | $934 |
| % Growth | 19.8% | 91% | 667.3% | – |
| Cost of Goods Sold | $1,687 | $1,283 | $817 | $141,836 |
| Gross Profit | $13,857 | $12,407 | $6,350 | -$140,902 |
| % Margin | 84.5% | 90.6% | 88.6% | -15,085.9% |
| R&D Expenses | $114,766 | $124,187 | $126,683 | $141,236 |
| G&A Expenses | $0 | $0 | $0 | $168,977 |
| SG&A Expenses | $72,001 | $75,490 | $73,490 | $70,821 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$98,156 |
| Other Operating Expenses | $259 | $258 | $259 | $600 |
| Operating Expenses | $187,026 | $199,677 | $200,173 | $212,057 |
| Operating Income | -$172,054 | -$187,270 | -$193,823 | -$211,723 |
| % Margin | -1,049.1% | -1,367.9% | -2,704.4% | -22,668.4% |
| Other Income/Exp. Net | $10,150 | $10,357 | $9,237 | $9,502 |
| Pre-Tax Income | -$161,904 | -$176,913 | -$184,586 | -$202,221 |
| Tax Expense | $0 | $0 | -$9,237 | $254 |
| Net Income | -$161,904 | -$176,913 | -$184,586 | -$202,475 |
| % Margin | -987.2% | -1,292.3% | -2,575.5% | -21,678.3% |
| EPS | -2.49 | -3.04 | -3.02 | -3.51 |
| % Growth | 18.1% | -0.7% | 14% | – |
| EPS Diluted | -2.49 | -3.04 | -3.02 | -3.51 |
| Weighted Avg Shares Out | 64,993 | 58,232 | 58,032 | 57,672 |
| Weighted Avg Shares Out Dil | 64,993 | 58,232 | 58,032 | 57,672 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,115 | $1,107 | $1,075 | $891 |
| EBITDA | -$170,939 | -$186,163 | -$186,598 | -$207,523 |
| % Margin | -1,042.3% | -1,359.8% | -2,603.6% | -22,218.7% |